deltatrials
Not Yet Recruiting PHASE1_PHASE2 Interventional 1-arm NCT03362892

A Phase I/II Study of ABTL0812 (Pancreatic) (Pancreatic)

A Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy

Sponsor: Ability Pharmaceuticals SL

Conditions Pancreatic Cancer
Interventions sodium 2-hydroxylinoleate
Updated 1 time since 2017 Last updated: Nov 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1_PHASE2 trial investigates Pancreatic Cancer and is currently actively recruiting participants. Ability Pharmaceuticals SL leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2017 – present · 104 months · monthly snapshotNot Yet Recruiting

Change History

1 version recorded
Not Yet Recruiting — PHASE1_PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ability Pharmaceuticals SL
Data source: Ability Pharmaceuticals SL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.